{"id":34572,"date":"2025-08-08T01:14:09","date_gmt":"2025-08-08T01:14:09","guid":{"rendered":"https:\/\/www.europesays.com\/it\/34572\/"},"modified":"2025-08-08T01:14:09","modified_gmt":"2025-08-08T01:14:09","slug":"curevac-risolve-il-contenzioso-sui-brevetti-con-pfizer-e-biontech-notizie-tradingview","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/it\/34572\/","title":{"rendered":"CureVac risolve il contenzioso sui brevetti con Pfizer e BioNTech \u2014 Notizie TradingView"},"content":{"rendered":"<p class=\"\">CureVac <a href=\"https:\/\/it.tradingview.com\/symbols\/NASDAQ-CVAC\/\" class=\"container-ekXxv5Y5 symbolTag-cwMMKgmm tag-zVPYJd3B xsmall-zVPYJd3B interactive-zVPYJd3B apply-overflow-tooltip apply-overflow-tooltip--allow-text apply-overflow-tooltip--check-children\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" class=\"logo-PsAlMQQF xxxsmall-PsAlMQQF wrapper-TJ9ObuLF skeleton-PsAlMQQF\" crossorigin=\"\" src=\"https:\/\/s3-symbol-logo.tradingview.com\/curevac.svg\" alt=\"\"\/>CVAC<\/a> ha detto *GIOVED\u00ec che l&#8217;azienda e GSK <a href=\"https:\/\/it.tradingview.com\/symbols\/LSE-GSK\/\" class=\"container-ekXxv5Y5 symbolTag-cwMMKgmm tag-zVPYJd3B xsmall-zVPYJd3B interactive-zVPYJd3B apply-overflow-tooltip apply-overflow-tooltip--allow-text apply-overflow-tooltip--check-children\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" class=\"logo-PsAlMQQF xxxsmall-PsAlMQQF wrapper-TJ9ObuLF skeleton-PsAlMQQF\" crossorigin=\"\" src=\"https:\/\/s3-symbol-logo.tradingview.com\/glaxosmithkline.svg\" alt=\"\"\/>GSK<\/a> hanno concluso un accordo per risolvere la controversia sui brevetti con Pfizer <a href=\"https:\/\/it.tradingview.com\/symbols\/NYSE-PFE\/\" class=\"container-ekXxv5Y5 symbolTag-cwMMKgmm tag-zVPYJd3B xsmall-zVPYJd3B interactive-zVPYJd3B apply-overflow-tooltip apply-overflow-tooltip--allow-text apply-overflow-tooltip--check-children\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" class=\"logo-PsAlMQQF xxxsmall-PsAlMQQF wrapper-TJ9ObuLF skeleton-PsAlMQQF\" crossorigin=\"\" src=\"https:\/\/s3-symbol-logo.tradingview.com\/pfizer.svg\" alt=\"\"\/>PFE<\/a> e BioNTech <a href=\"https:\/\/it.tradingview.com\/symbols\/NASDAQ-BNTX\/\" class=\"container-ekXxv5Y5 symbolTag-cwMMKgmm tag-zVPYJd3B xsmall-zVPYJd3B interactive-zVPYJd3B apply-overflow-tooltip apply-overflow-tooltip--allow-text apply-overflow-tooltip--check-children\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" class=\"logo-PsAlMQQF xxxsmall-PsAlMQQF wrapper-TJ9ObuLF skeleton-PsAlMQQF\" crossorigin=\"\" src=\"https:\/\/s3-symbol-logo.tradingview.com\/biontech.svg\" alt=\"\"\/>BNTX<\/a> relativa ai vaccini Covid-19 a base di mRNA. <\/p>\n<p class=\"\">Come parte dell&#8217;accordo, CureVac e GSK riceveranno un pagamento combinato di 740 milioni di dollari e royalties a una cifra sulle vendite dei vaccini Covid-19 negli Stati Uniti.<\/p>\n<p class=\"\">CureVac conceder\u00e0 inoltre a BioNTech e Pfizer una licenza non esclusiva per la produzione, l&#8217;uso, l&#8217;importazione e la vendita di prodotti Covid-19 e antinfluenzali a base di mRNA negli Stati Uniti.<\/p>\n","protected":false},"excerpt":{"rendered":"CureVac CVAC ha detto *GIOVED\u00ec che l&#8217;azienda e GSK GSK hanno concluso un accordo per risolvere la controversia&hellip;\n","protected":false},"author":3,"featured_media":2499,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1512],"tags":[239,1537,90,89,240,2189,2188,2187],"class_list":{"0":"post-34572","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-vaccini","8":"tag-health","9":"tag-it","10":"tag-italia","11":"tag-italy","12":"tag-salute","13":"tag-vaccine","14":"tag-vaccines","15":"tag-vaccini"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/posts\/34572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/comments?post=34572"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/posts\/34572\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/media\/2499"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/media?parent=34572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/categories?post=34572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/it\/wp-json\/wp\/v2\/tags?post=34572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}